sitagliptin + metformin + insulin glargine

This drug entity refers to a sequential combination treatment regimen evaluated in the JUBILEE (JanUmet Before Insulin Lantus In Eastern Population Evaluation Program) clinical trial conducted by the Chinese University of Hong Kong. The regimen consists of Janumet (a fixed-dose combination of sitagliptin and metformin) followed by the addition of Lantus (insulin glargine) for the management of Type 2 Diabetes Mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases insulin release and decreases glucagon levels. Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity. Insulin glargine is a long-acting basal insulin analogue that provides a steady level of insulin over 24 hours. The Phase 4 study specifically evaluated this regimen's efficacy and safety in achieving glycemic control with fewer hypoglycemic events compared to traditional sulfonylurea-based therapies in Chinese patients.

Brand names

JanumetLantus

Other names

Janumet + LantusJUBILEE regimensitagliptin + metformin + insulin glargine-Chinese University of Hong Kong-Type 2 Diabetes Mellitus